tiprankstipranks
Trending News
More News >

AnaptysBio price target raised to $54 from $52 at Guggenheim

Guggenheim analyst Yatin Suneja raised the firm’s price target on AnaptysBio (ANAB) to $54 from $52 and keeps a Buy rating on the shares. Following Q1 earnings, the firm says it is “encouraged by the company’s clinical development and its robust pipeline.”

Confident Investing Starts Here:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.

Report an Issue